Graham Capital Management, L.P. Denali Therapeutics Inc. Transaction History
Graham Capital Management, L.P.
- $4.38 Billion
- Q1 2025
A detailed history of Graham Capital Management, L.P. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 43,005 shares of DNLI stock, worth $628,733. This represents 0.01% of its overall portfolio holdings.
Number of Shares
43,005
Previous 20,706
107.69%
Holding current value
$628,733
Previous $421,000
38.72%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding DNLI
# of Institutions
234Shares Held
127MCall Options Held
37.3KPut Options Held
7.9K-
Black Rock Inc. New York, NY13.2MShares$193 Million0.01% of portfolio
-
Baillie Gifford & CO12.1MShares$177 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$173 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA11.4MShares$167 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.77MShares$98.9 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.96B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...